TMB may be characterized concerning illustration the aggregate number for physical mutations for every megabase or those nonsynonymous transformations in tumor tissues, including supplanting and insertion erasure changes, and has become a preferable biomarker to foresee the light of anti-PD-1/PD-L1 therapy [41, 42]. The gene discussed is PDCD1; the disease is neoplasm.